Clinical translation of nanomedicines: Challenges, opportunities, and keys
Despite the massive interest and recent developments in the field of nanomedicine, only a
limited number of formulations have found their way to the clinics. This shortcoming reveals …
limited number of formulations have found their way to the clinics. This shortcoming reveals …
[HTML][HTML] A review on drug delivery system for tumor therapy
G Liu, L Yang, G Chen, F Xu, F Yang, H Yu… - Frontiers in …, 2021 - frontiersin.org
In recent years, with the development of nanomaterials, the research of drug delivery
systems has become a new field of cancer therapy. Compared with conventional antitumor …
systems has become a new field of cancer therapy. Compared with conventional antitumor …
An updated review of folate-functionalized nanocarriers: A promising ligand in cancer
The uncontrolled release of drugs in conventional drug delivery systems has led to the
introduction of new nanotechnology-based drug delivery systems and the use of targeted …
introduction of new nanotechnology-based drug delivery systems and the use of targeted …
Drug delivery vehicles on a nano-engineering perspective
B Felice, MP Prabhakaran, AP Rodriguez… - Materials Science and …, 2014 - Elsevier
Nanoengineered drug delivery systems (nDDS) have been successfully used as clinical
tools for not only modulation of pharmacological drug release profile but also specific …
tools for not only modulation of pharmacological drug release profile but also specific …
Advanced smart nanomaterials with integrated logic-gating and biocomputing: dawn of theranostic nanorobots
AA Tregubov, PI Nikitin, MP Nikitin - Chemical reviews, 2018 - ACS Publications
Accurate and precise drug delivery is the key to successful therapy. Monoclonal antibodies,
which can transport therapeutic payload to cells expressing specific markers, have paved …
which can transport therapeutic payload to cells expressing specific markers, have paved …
[HTML][HTML] Anti-tumor activity of novel nimotuzumab-functionalized gold nanoparticles as a potential immunotherapeutic agent against skin and lung cancers
M Anisuzzman, V Komalla, MAM Tarkistani… - Journal of Functional …, 2023 - mdpi.com
The epidermal growth factor receptor (EGFR) is vital for many different types of cancer.
Nimotuzumab (NmAb), an anti-EGFR monoclonal antibody (mAb), is used against some of …
Nimotuzumab (NmAb), an anti-EGFR monoclonal antibody (mAb), is used against some of …
Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology
Nanoparticles are designed to deliver therapeutics and diagnostics selectively to tumors.
Their size, shape, charge, material, coating, and cargo determine their individual …
Their size, shape, charge, material, coating, and cargo determine their individual …
Preclinical evaluation and clinical translation of magnetite-based nanomedicines
JV Nuzhina, AA Shtil, AY Prilepskii… - Journal of Drug Delivery …, 2019 - Elsevier
Over the last decade, magnetic iron oxide nanoparticles have attracted considerable interest
in the field of nanomedicine due to their unique magnetic properties, biocompatibility, and …
in the field of nanomedicine due to their unique magnetic properties, biocompatibility, and …
Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics
SE Jin, HE Jin, SS Hong - BioMed research international, 2014 - Wiley Online Library
Targeted delivery systems of nanobiomaterials are necessary to be developed for the
diagnosis and treatment of cancer. Nanobiomaterials can be engineered to recognize …
diagnosis and treatment of cancer. Nanobiomaterials can be engineered to recognize …
[HTML][HTML] Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma
WK Nevala, JT Butterfield, SL Sutor, DJ Knauer… - Scientific reports, 2017 - nature.com
We developed a nano-antibody targeted chemotherapy (nATC) delivery strategy in which
tumor specific and clinically relevant antibodies (rituximab, anti-CD20) are non-covalently …
tumor specific and clinically relevant antibodies (rituximab, anti-CD20) are non-covalently …